Wedbush Has Pessimistic Outlook of TLX FY2025 Earnings

Key Points

• Wedbush analysts have decreased their FY2025 earnings per share (EPS) estimate for Telix Pharmaceuticals from $0.07 to $0.06, while maintaining an "Outperform" rating and a price target of $22.00.
• The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share, with further projected earnings increase to $0.30 EPS for FY2026.
• Telix Pharmaceuticals' stock has a current price of $10.15 and a 12-month high of $30.36, reflecting significant volatility in its trading performance.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - Equities research analysts at Wedbush cut their FY2025 earnings estimates for shares of Telix Pharmaceuticals in a note issued to investors on Thursday, August 28th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $0.06 per share for the year, down from their previous forecast of $0.07. Wedbush currently has a "Outperform" rating and a $22.00 target price on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share. Wedbush also issued estimates for Telix Pharmaceuticals' Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.10 EPS, FY2026 earnings at $0.30 EPS, Q1 2027 earnings at $0.12 EPS, Q2 2027 earnings at $0.12 EPS and FY2027 earnings at $0.54 EPS.

Several other brokerages also recently commented on TLX. HC Wainwright initiated coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They set a "buy" rating and a $23.00 price objective on the stock. William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $22.33.

Telix Pharmaceuticals Price Performance

Shares of NASDAQ:TLX traded down $0.15 during mid-day trading on Friday, reaching $9.40. The stock had a trading volume of 216,198 shares, compared to its average volume of 58,339. The firm has a 50 day simple moving average of $13.78 and a two-hundred day simple moving average of $15.98. Telix Pharmaceuticals has a twelve month low of $9.25 and a twelve month high of $30.36. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. IHT Wealth Management LLC acquired a new position in Telix Pharmaceuticals during the second quarter worth $213,000. Jane Street Group LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $564,000. Russell Investments Group Ltd. acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at about $975,000. Pier Capital LLC acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at about $3,037,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Telix Pharmaceuticals in the second quarter valued at approximately $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.